SCHEMBL20069712

SCHEMBL20069712

CC(C)CC(=O)NC1(CN2CCCC2)CCN(C)CC1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RET P07949 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
TP53 P04637 1/20 0.40
GAA P10253 3/20 0.35
SIGMAR1 Q99720 1/20 0.34
DPP4 P27487 1/20 0.34
TNKS2 Q9H2K2 1/20 0.33
NPY5R Q15761 1/20 0.32
POLB P06746 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HDAC4 P56524 1/20 0.31
ALDH1A1 P00352 1/20 0.31
FPR3 P25089 1/20 0.31
FPR2 P25090 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069716 0.89 RET (0.43) RETSMN1; SMN2TP53SIGMAR1DPP4
SCHEMBL20069522 0.88 RET (0.43) RETSMN1; SMN2TP53ALDH1A1
SCHEMBL20147518 0.87 RET (0.40) RETSMN1; SMN2TP53GAASIGMAR1
SCHEMBL20148041 0.85 RET (0.39) RETSMN1; SMN2TP53GAATNKS2
SCHEMBL20070061 0.82 SMN1; SMN2 (0.41) RETSMN1; SMN2TP53GAADPP4
SCHEMBL21651960 0.79 RET (0.41) RETTP53SIGMAR1HDAC4ALDH1A1
SCHEMBL20070368 0.79 RET (0.44) RETSMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL20069525 0.78 RET (0.41) RETSMN1; SMN2TP53GAADPP4
SCHEMBL20147508 0.77 RET (0.42) RETSMN1; SMN2TP53SIGMAR1TNKS2
SCHEMBL20147488 0.76 RET (0.42) RETSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
WO-2018071454-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ANDREWS STEVEN W (US) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RET 1/4885SMN1; SMN2 646/4885TP53 759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.